Treatment of heparin-induced thrombocytopenia in cardiovascular patients

Bibliography

• BREIGER DB, MAK KH, KOTTKE-MARCHANT K, TOPOL EJ: Heparin-induced thrombocytopenia. J. Am. Coll. Cardiol. (1998) 31:1449-1459.
   PubMedGoogle Scholar
• WALLS JT, CURTIS JJ, SILVER D et al.: Heparin-induced thrombocytopenia in open heart surgical patients: sequelae of late recognition. Ann. Thorac. Surg. (1992) 53:787-791.
   PubMed Web of Science ®Google Scholar
• SINGER RL, MANNION JD, BAUER TL, ARMENTI FR, EDIE RN: Complications from heparin-induced thrombocytopenia in patient undergoing cardiopulmonary bypass. Chest (1993) 104:1436-1440.
   PubMedGoogle Scholar
• CREAPO EM, BECKER RC, BERGER PB et al.: Evaluation and outcomes of thrombocytopenia developing while on heparin among cardiac care unit patients: insights from the complications after thrombocytopenia caused by heparin (CATCH) registry. Circulation (2004) 110:III-370.
   Google Scholar
• WEITZ JI, HIRSH J, SAMAMA MM: New anticoagulant drugs: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest (2004) 126:265S-286S.
   PubMed Web of Science ®Google Scholar
• GREINACHER A: Recombinant hirudin for the treatment of heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. TE Warkenitn, A Greinacher (Eds), Marcel Dekker, Inc., New York, NY, USA (2001):349-380.
   Google Scholar
• GREINACHER A, EICHLER P, LUBENOW N, KWASNY H, LUZ M: Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and it therapeutic aPTT range. Blood (2000) 96:846-851.
   PubMed Web of Science ®Google Scholar
• SONG X, HUHLE B, WANG L, HOFFMANN U, HARENBERG J: Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with R-hirudin. Circulation (1999) 100:1528-1532.
   PubMed Web of Science ®Google Scholar
• LIEBE V, BRUCKMANN M, FISCHER KG et al.: Biological relevance of anti-recombinant hirudin antibodies-results from in vitro and in vivo studies. Semin. Thromb. Hemost. (2002) 28:483-490.
   PubMed Web of Science ®Google Scholar
• GREINACHER A, LUBENOW N, EICHLER P: Anaphylactic and anaphylactoid reactions associated with lepirudin in patients with heparin-induced thrombocytopenia. Circulation (2004) 109:2062-2065.
   Google Scholar
• KOSTER A, MERKLE F, HANSEN R et al.: Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth. Analg. (2000) 91:265-269.
   PubMedGoogle Scholar
• HUHLE G, HOFFMANN U, HOFFMANN I et al.: A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: a pilot study. Thromb. Res. (2000) 99:325-334.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, WILLE-JORGENSEN P, KALEBO P et al.: A comparison of recombinant hirudin with a low-molecular weight heparin to prevent thromboembolic complications after total hip replacement. N. Engl. J. Med. (1997) 337:1329-1335.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, EKMAN S, LINDBRATT S et al.: Prevention of thromboemoblism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement. J. Bone Joint Surg. Am. (1997) 79:326-333.
   PubMedGoogle Scholar
• CLOSE P, BICHLER J, KERRY R et al.: Weak allergenicity of recombinant hirudin CGP 39393 (Revasc) in immunocompetent volunteers. The European Hirudin in Thrombosis Group (HIT Group). Coron. Artery Dis. (1994) 5:943-949.
   PubMed Web of Science ®Google Scholar
• GREINACHER A, EICHLER P, ALBRECHT A et al.: Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood (2003) 101:2617-2619.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, HURSTING ME: Argatroban therapy in heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. TE Warkenitn, A Greinacher (Eds), Marcel Dekker, Inc., New York, NY, USA (2001):381-407.
   Google Scholar
• BARTHOLOMEW J: Transition to an oral anticoagulant in patients with heparin-induced thrombocytopenia. Chest (2005) 127:27S-34S.
   Web of Science ®Google Scholar
• MATTHAI WH, HURSTING MJ, LEWIS BE, KELTON JG: Argatroban anticoagulation in patients with a history of heparin-induced thrombocytopenia. Thromb. Res. (2005) 116:121-126.
   PubMed Web of Science ®Google Scholar
• MAHAFFEY KW, LEWIS BE, WILDERMANN NM et al.: The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. J. Invasive Cardiol. (2003) 15:622-623.
   PubMedGoogle Scholar
• LINCOFF AM, KLEIMAN NS, KEREIAKES DJ et al.: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA (2004) 292:696-703.
   PubMed Web of Science ®Google Scholar
• CHEW DP, LINCOFF AM, GURM H et al.: Bivalirudin versus heparin and glycoprotein IIb/IIIa inhibition among patient with renal impairment undergoing percutaneous coronary intervention (a subanalysis of the REPLACE-2 trial). Am. J. Cardiol. (2005) 95:581-585.
   PubMed Web of Science ®Google Scholar
• EICHLER P, LUBENOW N, STROBEL U, GREINACHER A: Antibodies against lepirudin are polyspecific and recognize epitopes on bivalirudin. Blood (2004) 103:613-616.
   PubMed Web of Science ®Google Scholar
• DANHOF M, DE BOER A, MAGNANI HN, STIEKEMA JC: Pharmacokinetic considerations on Orgaran (Org 10172) therapy. Haemostasis (1992) 22:73-84.
   PubMedGoogle Scholar
• MAGNANI HN: Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb. Haemost. (1993) 70:554-561.
   PubMed Web of Science ®Google Scholar
• KENG TB CHONG BH: Heparin-induced thrombocytopenia and thrombosis syndrome: in vivo corss-reactivity with danaparoid and successful treatment with R-hirudin. Br. J. Haematol. (2001) 114:394-396.
   PubMedGoogle Scholar
• WARKENTIN TE, COOK RJ, MARDER VJ, KELTON JG: Comparison of heparin-induced thrombocytopenia antibody (HIT-Ab) generation and in vitro cross-reactivity after elective hip or knee replacement surgery in patients receiving antithrombotic prophylaxis with fondaparinux or enoxaparin. Blood (2003) 102: Abstract 569.
   Google Scholar
• AHMAD S, JESKE WP, WALENGA JM et al.: Synthetic pentasaccharides do not cause platelet activation by antiheparin-platelet factor 4 antibodies. Clin. Appl. Thromb. Hemost. (1999) 5:259-266.
   PubMed Web of Science ®Google Scholar
• SAVI P, CHONG BH, GREINACHER A et al.: Effect of fondaparinux on platelet activation in the presence of heparin-dependent antibodies: a blinded comparative multicenter study with unfractionated heparin. Blood (2005) 105:139-144.
   PubMed Web of Science ®Google Scholar
• HAASE M, BELLOMO R, ROCKTAESCHEL J et al.: Use of fondaparinux (Arixtra) in a dialysis patient with symptomatic heparin-induced thrombocytopenia type II. Nephrol. Dial. Transplant. (2005) 20:444-446.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, MATTHAI WH, COHEN M et al.: Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet. Cardiovasc. Intervent. (2002) 57:177-184.
   PubMed Web of Science ®Google Scholar
• JANG IK, LEWIS BE, MATTHAI WH, KLEIMAN NS: Argatroban anticoagulation in conjunction with glycoprotein IIb/IIIa inhibition in patients undergoing percutaneous coronary intervention: an open-label, nonrandomized pilot study. J. Thromb. Thrombolysis (2004) 18:31-37.
   PubMed Web of Science ®Google Scholar
• SERRUYS PW, HERRMAN JP, SIMON R et al.: A comparison of hirudin with heparin in the prevention of restenosis after coronary angioplasty. N. Engl. J. Med. (1995) 333:757-763.
   PubMed Web of Science ®Google Scholar
• MEHTA SR, STEG PG, GRANGER CG et al.: Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention. Circulation (2005) 111:1390-1397.
   PubMed Web of Science ®Google Scholar
• GREINACHER A, HANSSEND U, BERG G et al.: Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation (1999) 100:587-593.
   PubMed Web of Science ®Google Scholar
• GREINACHER A, VOLLPEL H, HANSSENS U et al.: Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients wih heparin-induced thrombocytopenia. Circulation (1999) 99:73-80.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, WALLIS DE, BERKOWITZ SD et al.: Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation (2001) 103:1838-1843.
   PubMed Web of Science ®Google Scholar
• LEWIS BE, WALLIS DE, LEYA F et al.: Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Arch. Int. Med. (2003) 163:1849-1856.
   PubMed Web of Science ®Google Scholar
• ORGANISATION TO ASSESS STRATEGIES FOR ISCHEMIC SYNDROMES (OASIS-2) INVESTIGATORS: Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial infarction without ST elevation: a randomised trial. Lancet (1999) 353:429-438.
   PubMed Web of Science ®Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES (GUSTO) IIB INVESTIGATORS: A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes. N. Engl. J. Med. (1996) 335:775-782.
   PubMed Web of Science ®Google Scholar
• SIMOONS ML, BOBBINK IW, BOLAND J et al.: A dose-finding study of fondaparinux in patients with non-ST-segment elevation acute coronary syndromes: the pentasaccharide in unstable angina (PENTUA) Study. J. Am. Coll. Cardiol. (2004) 43:2183-2190.
   PubMed Web of Science ®Google Scholar
• THE HIRULOG AND EARLY REPERFUSIO ON OCCLUSION (HERO)-2 TRIAL INVESTIGATORS: Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction; the HERO-2 randomised trial. Lancet (2001) 358:1855-1863.
   PubMed Web of Science ®Google Scholar
• THE GLOBAL USE OF STRATEGIES TO OPEN OCCLUDED CORONARY ARTERIES (GUSTO) IIA INVESTIGATORS: Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation (1994) 90:1631-1637.
   PubMed Web of Science ®Google Scholar
• JANG IK, BROWN DF, GIUGLIANO RP et al.: A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction and novastan and TPA (MINT) study. J. Am. Coll. Cardiol. (1999) 33:1879-1885.
   PubMed Web of Science ®Google Scholar
• WARKENTIN TE, KELTON JG: Temporal aspects of heparin-induced thrombocytopenia. N. Engl. J. Med. (2001) 344:1286-1292.
   PubMed Web of Science ®Google Scholar
• POETZSCH B, MADLENER K: Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In: Heparin-Induced Thrombocytopenia. TE Warkenitn, A Greinacher (Eds), Marcel Dekker, Inc., New York, NY, USA (2001):429-444.
   Google Scholar
• WARKENTIN TE, GREINACHER A: Heparin-induced thrombocytopenia and cardiac surgery. Ann. Thoracic Surg. (2003) 76:638-648.
   PubMedGoogle Scholar
• KOSTER A, HANSEN R, KUPPE H et al.: Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin –induced thrombocytopenia type II: a 1-year experience n 57 patients. J. Cardiothorac. Vasc. Anesth. (2000) 14:243-248.
   PubMed Web of Science ®Google Scholar
• GREINACHER A: The use of direct thrombin inhibitors in cardiovascular surgery in patients with heparin-induced thrombocytopenia. Semin. Thromb. Hemost. (2004) 30:315-327.
   PubMed Web of Science ®Google Scholar
• KOSTER A, SPIESS B, CHEW DP et al.: Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am. J. Cardiol. (2004) 93:356-359.
   PubMed Web of Science ®Google Scholar
• JABR K, JOHNSON JH, MCDONALD MH et al.: Plasma-modified ACT can be used to monitor bivalirudin (Amgiomax) anticoagulation for on-pump cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J. Extra. Corpor. Technol. (2004) 36:174-177.
   PubMedGoogle Scholar
• WARKENTIN TE, ELAVATHIS LJ, HAYWARD CP et al.: The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia. Ann. Intern. Med. (1997) 127:804-812.
   PubMed Web of Science ®Google Scholar
• TURPIE AG, ERIKSSON BI, BAUER KA et al.: New pentasaccharides for the prophylaxis of venous thromboembolism. Chest (2003) 124:S371-S378.
   Google Scholar